Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...

Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that the SELECT-MDS-1 Phase 3 ...

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today.

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment... On Wednesday ...

Gainers: NATR +26%. AKBA +17%. ELMD +9%. SYRS +9%. NEPT +8%.Losers: ETRM -25%. MIRN -23%. IMUC -18%. PTX -17%. BVX -17%.Now read: Biotech Forum Daily Digest: Citron ...

Kia has officially revealed the name of its upcoming compact SUV and contrary to previous reports, it will be called “Syros”. Although Kia did file a trademark application for the “Syros ...

Short interest in Syros Pharmaceuticals Inc (NASDAQ:SYRS) decreased during the last reporting period, falling from 999.93K to 952.60K. This put 3.87% of the company's publicly available shares short.

Kia aims to create vehicles that deeply resonate with customers. Advt “Syros will be the first Kia 2.0 SUV offering after Carnival and EV9. It will represent a new chapter in Kia's journey ...

Shortly after the teaser sketches of the new SUV were revealed, we have now got to know that it will be now called the Kia Syros. The name ‘Syros’ – which was trademarked by the carmaker in ...